The third quarter of 2019 has ended with major acquisitions in the pharma and biotech industry along with multiple approvals. Starting with the latest acquisition where Biocon Biologics acquires Pfizer’s Research Facility for expansion of its R&D footprints with the acceleration of the development of its biosimilars from lab to pilot scale. Previously, Amgen acquired […]Read More
Shots: Sobi acquires Dova Pharmaceutical in cash & stock transaction making a total deal value as $915M. Dova to receive upfront of $27.50/share in cash, $1.50/share on approval of Doptelet as CVR, representing a total consideration of up to $29.00/share with a premium of 36% to Dova’s closing price on Sept 27, 2019 The focus […]Read More
Shots: Dova Pharmaceuticals to pay Salix Pharmaceuticals, a quarterly fee on the US sales. Salix to deploy ~100 specialists for promotion of Doptelet which is expected to launch in mid-Oct 2018 Doptelet is approved by FDA on 21 May, 2018 for thrombocytopenia in adult patients with chronic liver disease (CLD). The approval is based on […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
